Global Lung Cancer Surgery Market 2024–2033

Reports Description

As per the current market research conducted by the CMI Team, the global Lung Cancer Surgery Market is expected to record a CAGR of 6.1% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 1.3 Billion. By 2033, the valuation is anticipated to reach USD 2.6 Billion.

The lung cancer surgery market encompasses medical procedures aimed at treating lung cancer through surgical interventions. Its nature involves a multidisciplinary approach integrating surgery with chemotherapy, radiation therapy, and targeted therapies.

Key trends include a shift towards minimally invasive techniques like video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgery, advancements in imaging modalities for accurate staging, and personalized treatment strategies based on genetic profiling.

Additionally, there is a growing emphasis on early detection and screening programs to enhance patient outcomes.

Lung Cancer Surgery Market – Significant Growth Factors

The Lung Cancer Surgery Market presents significant growth opportunities due to several factors:

• Minimally Invasive Techniques: Demand for minimally invasive lung cancer surgeries, such as VATS and robotic-assisted procedures, is rising due to reduced patient trauma, quicker recovery times, and improved surgical outcomes. This trend is driven by advancements in surgical instruments, imaging technologies, and surgeon expertise, offering opportunities for companies to innovate and expand their product portfolios catering to this growing segment of patients.

• Targeted Therapies: The advent of targeted therapies, including immunotherapy and molecularly targeted agents, presents opportunities for personalized treatment approaches based on the genetic profile of individual patients. Companies investing in research and development to identify biomarkers and develop novel therapeutics stand to capitalize on the growing demand for precision medicine in lung cancer treatment.

• Integration of Robotics: The integration of robotic-assisted surgery systems enables surgeons to perform complex lung cancer surgeries with enhanced precision and control. Opportunities exist for companies developing robotic platforms to further refine their technologies, expand indications, and streamline surgical workflows, thereby improving patient outcomes and driving market growth.

• Advancements in Imaging: Continued advancements in imaging modalities, such as positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT), facilitate accurate staging and preoperative planning for lung cancer surgeries. Companies offering innovative imaging solutions tailored to the specific needs of lung cancer patients can capitalize on the growing demand for enhanced diagnostic accuracy and treatment planning.

• Personalized Medicine: The growing emphasis on personalized medicine in lung cancer treatment, driven by advancements in genomic profiling and biomarker testing, offers opportunities for companies to develop companion diagnostics and targeted therapies tailored to individual patients’ molecular profiles. This trend fosters collaboration between pharmaceutical companies, diagnostic firms, and healthcare providers to deliver more effective and personalized treatment regimens.

• Early Detection Initiatives: Increasing awareness of the importance of early detection and screening programs for lung cancer among high-risk populations, such as smokers and individuals with a family history of the disease, presents opportunities for companies offering screening technologies, diagnostic tests, and telemedicine solutions. Investing in outreach programs and partnerships with healthcare providers can help companies capitalize on this growing market segment.

• Multidisciplinary Care: The adoption of multidisciplinary care models, involving collaboration among surgeons, medical oncologists, radiation oncologists, and other healthcare professionals, is becoming increasingly prevalent in the management of lung cancer. Companies offering integrated healthcare solutions, including care coordination platforms and telehealth services, can leverage this trend to improve patient outcomes and optimize resource utilization across the care continuum.

Lung Cancer Surgery Market – Mergers and Acquisitions

The lung cancer surgery market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the lung cancer surgery market include:

• In June 2021, Intuitive introduced SureForm, a robotic-assisted surgical stapler.

• In December 2020, Medtronic Private Limited released the EEA Circular Stapler with Tri-Staple Technology, the first of its kind in India, featuring varied height staples in a three-row configuration.

• In April 2019, Johnson & Johnson finalized the acquisition of Auris Health Inc., a manufacturer specializing in robotic platform technology.

These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the lung cancer surgery market. The trend is expected to continue as companies seek to gain a competitive edge in the market.

COMPARATIVE ANALYSIS OF THE RELATED MARKET

Lung Cancer Surgery Market	Cancer Monoclonal Antibodies Market	Cancer Monoclonal Antibody Testing Market
CAGR 6.1% (Approx)	CAGR 8.2% (Approx)	CAGR 7.6% (Approx)
USD 2.6 Billion by 2032	USD 231.4 Billion by 2033	USD 175.1 Billion by 2033

Lung Cancer Surgery Market – Significant Threats

The lung cancer surgery market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

• Late-stage diagnosis: Delayed detection of lung cancer can lead to advanced disease stages, limiting the effectiveness of surgical interventions and potentially reducing patient survival rates.

• Treatment resistance: The development of resistance to conventional therapies, such as chemotherapy and targeted agents, can diminish the efficacy of surgical treatments and contribute to disease recurrence.

• Surgical complications: Lung cancer surgeries carry inherent risks, including postoperative complications such as infections, bleeding, and impaired lung function, which can impact patient outcomes and increase healthcare costs.

• Limited access to care: Socioeconomic disparities and geographical barriers may limit access to specialized lung cancer surgical services, particularly in rural or underserved areas, exacerbating disparities in healthcare outcomes.

• Alternative treatment modalities: The emergence of alternative treatment modalities, such as stereotactic body radiation therapy (SBRT) and immunotherapy, as alternatives to surgery for certain patient populations, poses a competitive threat to traditional surgical approaches.

• Regulatory challenges: Stringent regulatory requirements and lengthy approval processes for new surgical technologies and innovations may hinder market entry and innovation within the lung cancer surgery market.

• Reimbursement limitations: Inadequate reimbursement policies and reimbursement cuts for lung cancer surgeries and related procedures may impact healthcare provider reimbursement rates and financial sustainability, potentially affecting the availability and affordability of surgical treatments.

• Public health policies: Shifting public health priorities and policies, such as anti-smoking campaigns and tobacco control measures, may impact the prevalence of lung cancer and subsequent demand for surgical interventions.

• Technological disruptions: Rapid advancements in non-invasive diagnostic technologies, such as liquid biopsy and molecular imaging, may lead to shifts in treatment paradigms and reduce the reliance on surgical interventions for lung cancer management.

• Economic factors: Economic downturns, healthcare budget constraints, and fluctuations in healthcare spending may influence investment decisions, research funding, and market growth within the lung cancer surgery sector.

Category-Wise Insights

By Product

• Thoracoscopes: Thoracoscopes are minimally invasive surgical instruments used to visualize and access the thoracic cavity during lung cancer surgeries. Trends in thoracoscopy include advancements in optics and imaging technology, enabling high-definition visualization and enhanced diagnostic capabilities. Additionally, there’s a shift towards smaller, more maneuverable thoracoscopes, facilitating precise surgical interventions with reduced patient trauma and faster recovery times.

• Mediastinoscopes: Mediastinoscopes are specialized instruments used for examining the mediastinum, aiding in the staging and biopsy of lung cancer. Trends involve the development of flexible and articulating mediastinoscopes, allowing for improved access to challenging anatomical regions and enhancing diagnostic accuracy. Moreover, integration with advanced imaging modalities such as endobronchial ultrasound (EBUS) enhances procedural guidance and diagnostic yield.

• Bronchoscopes: Bronchoscopes are flexible or rigid instruments utilized to visualize the airways and perform diagnostic and therapeutic procedures in lung cancer patients. Trends in bronchoscopy include the integration of advanced imaging technologies such as virtual bronchoscopy and navigational systems, enabling precise localization of lesions and targeted biopsies. Additionally, the miniaturization of bronchoscopes facilitates access to peripheral lung lesions, expanding the scope of bronchoscopic interventions in lung cancer diagnosis and treatment.

• Robotic-Assisted Thoracic Surgery Systems: Robotic-assisted thoracic surgery systems employ robotic technology to enhance the precision and dexterity of surgical procedures in lung cancer patients. Trends involve the development of next-generation robotic platforms with improved ergonomics, enhanced visualization, and advanced instrument manipulation capabilities. Additionally, advancements in artificial intelligence (AI) and image-guided navigation systems further augment the safety and efficacy of robotic-assisted thoracic surgeries.

• Surgical Staplers: Surgical staplers are crucial instruments for tissue approximation and hemostasis during lung cancer surgeries. Trends in surgical staplers include the introduction of powered stapling systems with integrated feedback mechanisms, ensuring optimal staple formation and tissue compression. Furthermore, the adoption of disposable and reloadable stapler cartridges enhances procedural efficiency while reducing the risk of cross-contamination and surgical site infections.

• Surgical Energy Instruments: Surgical energy instruments, such as electrocautery devices and ultrasonic dissectors, deliver controlled energy to tissues during lung cancer surgeries for cutting, coagulation, and hemostasis. Trends involve the development of advanced energy modalities with improved safety profiles, precision, and versatility. Additionally, integration with advanced sealing technologies enables efficient tissue sealing and vessel ligation, minimizing thermal damage and enhancing surgical outcomes in lung cancer patients.

By Application

• Lobectomy: Lobectomy involves the removal of an entire lobe of the lung affected by cancer. This procedure is typically performed when the tumor is localized within a specific lobe, aiming to eliminate cancerous tissue while preserving as much lung function as possible. Trends in lobectomy include advancements in minimally invasive techniques such as VATS, which offer reduced postoperative complications and faster recovery times.

• Segmentectomy: Segmentectomy entails the removal of a segment of the lung containing the tumor, preserving healthy lung tissue. This approach is increasingly utilized for early-stage lung cancers in patients with limited lung function, aiming to balance oncological outcomes with lung preservation. Trends in segmentectomy include refinements in surgical techniques and imaging modalities for precise segment identification and resection.

• Wedge Resection: Wedge resection involves the removal of a small, wedge-shaped portion of the lung containing the tumor. This procedure is typically employed for small, peripheral lung nodules or early-stage tumors, offering a less invasive alternative to lobectomy or segmentectomy. Trends in wedge resection focus on improving intraoperative imaging and navigation techniques to ensure accurate tumor localization and complete resection while minimizing tissue trauma.

• Pneumonectomy: Pneumonectomy is the complete surgical removal of one entire lung and is typically reserved for cases of extensive or centrally located lung tumors. While less commonly performed due to its significant impact on lung function, pneumonectomy remains a crucial treatment option for select patients with advanced lung cancer. Trends in pneumonectomy include advancements in perioperative care, such as enhanced recovery protocols, to optimize outcomes and reduce postoperative morbidity.

By Type

• Hospitals: Hospitals in the lung cancer surgery market refer to medical facilities equipped with comprehensive resources for diagnosing, treating, and managing lung cancer. Trends in hospital-based lung cancer surgery involve the integration of advanced technologies such as robotic-assisted surgery and minimally invasive techniques like video-assisted thoracoscopic surgery (VATS). Additionally, there is a growing emphasis on multidisciplinary care approaches within hospital settings, fostering collaboration among surgeons, oncologists, radiologists, and other specialists to optimize patient outcomes. Hospitals are also investing in patient-centred initiatives, including supportive care services and survivorship programs, to enhance the overall quality of care for lung cancer patients.

• Ambulatory Surgical Centres: Ambulatory Surgical Centres (ASCs) provide outpatient surgical procedures, including certain lung cancer surgeries that do not require overnight hospitalization. Trends in ASC-based lung cancer surgery focus on enhancing efficiency, convenience, and cost-effectiveness for patients. ASCs are increasingly adopting minimally invasive surgical techniques, such as robotic-assisted procedures and VATS, to facilitate shorter recovery times and faster discharge. Moreover, ASCs are leveraging technological advancements in anaesthesia and monitoring systems to ensure patient safety and comfort during procedures. The growing demand for same-day surgeries and the shift towards value-based care models are driving the expansion of lung cancer surgery services in ASCs.

Report Scope

Feature of the Report	Details
Market Size in 2024	USD 1.3 Billion
Projected Market Size in 2033	USD 2.6 Billion
Market Size in 2023	USD 1.2 Billion
CAGR Growth Rate	6.1% CAGR
Base Year	2023
Forecast Period	2024-2033
Key Segment	By Product, Application, End-User and Region
Report Coverage	Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope	North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options	Request tailored purchasing options to fulfil your requirements for research.

Lung Cancer Surgery Market – Regional Analysis

The Lung Cancer Surgery Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

• North America: North America’s lung cancer surgery market comprises the United States and Canada, characterized by advanced healthcare infrastructure and high adoption rates of innovative surgical techniques like robotic-assisted surgery. Trends include increasing investment in research and development, adoption of personalized medicine approaches, and emphasis on early detection and screening programs.

• Europe: In Europe, the lung cancer surgery market spans countries with diverse healthcare systems. Trends include a focus on multidisciplinary care models, integration of advanced imaging technologies, and growing utilization of minimally invasive surgical techniques to improve patient outcomes and reduce healthcare costs.

• Asia-Pacific: The Asia-Pacific region encompasses diverse markets with varying levels of healthcare infrastructure. Trends include rising healthcare expenditure, adoption of robotic-assisted surgery systems, and increasing awareness of lung cancer screening and treatment options. Additionally, collaborations between local and international healthcare providers drive the adoption of best practices and technological advancements in lung cancer surgery.

• LAMEA: LAMEA’s lung cancer surgery market comprises regions with emerging healthcare systems. Trends include efforts to enhance access to surgical services, adoption of telemedicine and digital health solutions for remote patient management, and partnerships with international organizations to improve healthcare infrastructure and capacity for lung cancer diagnosis and treatment.

Competitive Landscape – Lung Cancer Surgery Market

The Lung Cancer Surgery Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:

• Medtronic plc
• Ethicon Inc. (a subsidiary of Johnson & Johnson)
• Intuitive Surgical Inc.
• Olympus Corporation
• Accuray Incorporated
• AngioDynamics Inc.
• CONMED Corporation
• Teleflex Incorporated
• Ackermann Instrumente GmbH
• Scanlan International Inc.
• Sklar Surgical Instruments
• Microline Surgical
• KARL STORZ SE & Co. KG
• Braun Melsungen AG
• Richard Wolf GmbH
• Others

These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.

New players adopting innovation to enter the Lung Cancer Surgery market include startups like Verb Surgical, which focuses on developing advanced robotic-assisted surgical systems, and companies like Guardant Health, pioneering liquid biopsy technologies for non-invasive cancer detection and monitoring.

Key players dominating the Lung Cancer Surgery market include established medical device companies like Medtronic, Intuitive Surgical, and Ethicon (a subsidiary of Johnson & Johnson). These companies lead through a combination of technological innovation, extensive R&D investments, strategic partnerships with healthcare providers, and strong market presence, offering comprehensive solutions for lung cancer diagnosis and treatment.

The Lung Cancer Surgery Market is segmented as follows:

By Product

• Thoracoscopes
• Mediastinoscopes
• Bronchoscopes
• Robotic-Assisted Thoracic Surgery Systems
• Surgical Staplers
• Surgical Energy Instruments

By Application

• Lobectomy
• Segmentectomy
• Wedge Resection
• Pneumonectomy

By End-User

• Hospitals
• Ambulatory Surgical Centers

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America